<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940378</url>
  </required_header>
  <id_info>
    <org_study_id>LEVICC-001</org_study_id>
    <nct_id>NCT03940378</nct_id>
  </id_info>
  <brief_title>Treatment of Advanced Intrahepatic Cholangiocarcinoma</brief_title>
  <acronym>TAICC</acronym>
  <official_title>The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luoyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anyang Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third People's Hospital of Jiaozuo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanmenxia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>pinmei Group General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the&#xD;
      treatment of patients with advanced intrahepatic cholangiocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrahepatic cholangiocarcinoma(ICC) ,a kind of Hepatocellular carcinoma, is the sixth most&#xD;
      common cancer and thesecond leading cause of cancer-related deaths in the world.Currently,&#xD;
      Surgical resection is still the main treatment methods of early the ICC, but that is high&#xD;
      recurrent . Levamisole Hcl is a broad spectrum of intestinal worm medicine, our previous&#xD;
      study have found levamisole could significantly promote the apoptosis of bile duct cancer&#xD;
      cells, restrain the progress of the bile duct carcinoma in clinic and prolong survival&#xD;
      time.This drug is applicable to a variety of reasons caused by intrahepatic bile duct&#xD;
      carcinoma and extrahepatic bile duct carcinoma,so we carry out the study to evaluate the&#xD;
      efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic&#xD;
      cholangiocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time from start of treatment until the first documented event of symptomatic progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>48 months</time_frame>
    <description>Time from start of treatment to death from any cause, or last known date of survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>28 days</time_frame>
    <description>the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount</description>
  </other_outcome>
  <other_outcome>
    <measure>The change of AFP biomarker</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Concentration of AFP biomarker change in tumor markers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>ICC</condition>
  <arm_group>
    <arm_group_label>One-drug Regimes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basic drug : Anlotinib Hydrochloride Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two-Drug Regimens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levamisole Hydrochloride</intervention_name>
    <description>Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;</description>
    <arm_group_label>Two-Drug Regimens</arm_group_label>
    <other_name>LH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride Capsules</intervention_name>
    <description>Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;</description>
    <arm_group_label>One-drug Regimes</arm_group_label>
    <arm_group_label>Two-Drug Regimens</arm_group_label>
    <other_name>AHC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Ages 18-65 years&#xD;
&#xD;
          -  2. The diagnosis of ICC: in accordance with &quot;diagnostic and treating standards on&#xD;
             primary liver cancer&quot; or histological/cytological diagnosis of primary liver cancer&#xD;
&#xD;
          -  3. Un-resectable HCC : patients with developing primary liver cancer of Barcelona&#xD;
             stage(BCLC) B; multiple nodules (less than 5, the total diameter of less than 20 cm),&#xD;
             no invasion, no symptoms;refusing open surgical treatment and volunteering for the&#xD;
             treatment&#xD;
&#xD;
          -  4. The First-line system therapy failure (or residual lesion) from the group of this&#xD;
             study a signed informed consent (time) for 2 weeks or more basic returned to normal&#xD;
             and adverse events (NCI CTCAE Ⅰ level or less);&#xD;
&#xD;
          -  5. Child-Pugh liver function class A/B(score: ≤7)&#xD;
&#xD;
          -  6. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale in&#xD;
             one week before admission&#xD;
&#xD;
          -  7. Estimated survival time &gt; 3 months&#xD;
&#xD;
          -  8. HBV DNA#2000 IU/ml#10^4 copies/ml); or HBV DNA≥2000 IU/ml and are accepting&#xD;
             effective antiviral therapy&#xD;
&#xD;
          -  9. The major organ function is normal. that is meeting the following standards:&#xD;
&#xD;
               1. Blood routine examination: (No blood transfusion, no G-CSF and no medication were&#xD;
                  corrected within 14 days before screening)&#xD;
&#xD;
                  a.HB≥80g/L# b.ANC≥1.5×109/L#c.PLT≥50×109/L#&#xD;
&#xD;
               2. Biochemical examination: (ALB was not transfused within 14 days before screening)&#xD;
                  a.ALB ≥29 g/L# b.ALT#AST&lt;5ULN#c.TBIL ≤3ULN#d.creatinine&#xD;
&#xD;
                    -  1.5ULN( albumin and bilirubin, two indicators of Child-Pugh liver function&#xD;
                       class, can only have one for 2 points)&#xD;
&#xD;
          -  10. For women of childbearing age, the results of serum/urine pregnancy tests must be&#xD;
             negative within 7 days before initiation of treatment. All men and women who&#xD;
             participate in the study have to take reliable contraceptive measures within the trial&#xD;
             and eight weeks after the trial is completed&#xD;
&#xD;
          -  11. volunteers must signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. With a history of alimentary tract hemorrhage or a definite tendency of&#xD;
             gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with&#xD;
             bleeding risk; local active ulcer lesions; fecal occult blood ≥#++#&#xD;
&#xD;
          -  2. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell&#xD;
             carcinoma; in the past (within 5 years) or at the same time suffering from other&#xD;
             untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in&#xD;
             situs of cervix&#xD;
&#xD;
          -  3. Patients who are undergoing liver transplantation or have a history of organ&#xD;
             transplantation(excluding the patient who has undergone liver transplantation before)&#xD;
&#xD;
          -  4. Patients with an allergic history of Levamisole Hydrochloride and Anlotinib&#xD;
             Hydrochloride Capsules&#xD;
&#xD;
          -  5. The blood pressure can not be reduced to the normal range by the antihypertensive&#xD;
             drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic&#xD;
             pressure#90 mmHg)&#xD;
&#xD;
          -  6. Patients with myocardial ischemia or myocardial infarction over grade II or a&#xD;
             poorly controlled arrhythmia (including QTc interval: men ≥ 450 ms; women ≥ 470 ms)&#xD;
&#xD;
          -  7. Cardiac functional insufficiency of grade III to IV according to NYHA standard;&#xD;
             echocardiography: LVEF#50%&#xD;
&#xD;
          -  8. Many factors that influence oral medication, such as unable to swallow; chronic&#xD;
             diarrhea; intestinal obstruction; the situations which significantly affect the use&#xD;
             and absorption of drugs&#xD;
&#xD;
          -  9. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred&#xD;
             within 28 days before participating the study&#xD;
&#xD;
          -  10. Dysfunction of blood coagulation(INR#2.0 or PT# 16s#APTT &gt; 43s#TT &gt; 21s#Fbg &lt;&#xD;
             2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy;&#xD;
             ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis&#xD;
             or drainage or Child-Pugh score ≥2&#xD;
&#xD;
          -  11. Objective evidence of pulmonary fibrosis history, interstitial pneumonia,&#xD;
             pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung&#xD;
             function impairment in the past and at present&#xD;
&#xD;
          -  12. Urine routine showed that urine protein ≥++ or the urine protein in 24 hours#1.0 g&#xD;
&#xD;
          -  13. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole,&#xD;
             itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin,&#xD;
             erythromycin, cimetidine and so on) within 28 days before participating the study, or&#xD;
             potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine,&#xD;
             phenobarbitone and so on) within 12 days before participating the study.&#xD;
&#xD;
          -  14. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt&#xD;
             effective contraceptives&#xD;
&#xD;
          -  15. Patients with mental sickness or the history of psychotropic drug abuse&#xD;
&#xD;
          -  16. Patients with severe infection (unable to control the infection effectively)&#xD;
&#xD;
          -  17. The treatment history affecting this program or its efficacy, such as stem cell&#xD;
             transplantation, immune regulation (including PD-1 and other test regimens) recently&#xD;
             (within half a year)&#xD;
&#xD;
          -  18. The researchers believe that any other factors unsuitable for entering into the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zujiang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zujiang Yu, pro</last_name>
    <phone>0086-0371-67966942</phone>
    <email>johnyuem@zzu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zujiang Yu, pro</last_name>
      <phone>0086-0371-67966942</phone>
      <email>johnyuem@zzu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Juan Li, pro</last_name>
      <phone>0086-0371-67966942</phone>
      <email>ananli1984@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>May 4, 2019</last_update_submitted>
  <last_update_submitted_qc>May 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Zujiang YU</investigator_full_name>
    <investigator_title>The director of infectious diseases department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levamisole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

